| Literature DB >> 21237672 |
Ingo Jordan1, Stefan Northoff, Michael Thiele, Stefan Hartmann, Deborah Horn, Kristin Höwing, Holger Bernhardt, Stefanie Oehmke, Henning von Horsten, Dierk Rebeski, Lars Hinrichsen, Vladimir Zelnik, Wiebke Mueller, Volker Sandig.
Abstract
Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accommodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21237672 DOI： 10.1016/j.biologicals.2010.11.005
Source DB: PubMed Journal: Biologicals ISSN： 1045-1056 Impact factor: 1.856